Quoin Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 4
- Market Cap
- $2.4M
- Introduction
Quoin Pharmaceuticals Ltd. engages in the development of therapeutic products for the treatment of rare and orphan diseases. Its product pipeline includes QRX003, QRX004, QRX007, and QRX008. The company was founded by Michael Myers and Denise Carter on March 5, 2018 and is headquartered in Ashburn, VA.
Quoin Pharmaceuticals' QRX003 Shows Promise in Netherton Syndrome Trial
Quoin Pharmaceuticals' QRX003 demonstrates significant symptom reduction in a Netherton Syndrome clinical trial, with an 83% improvement observed in the first subject after 12 weeks.
Quoin Pharmaceuticals Expands QRX003 Clinical Program for Netherton Syndrome and Peeling Skin Syndrome
Quoin Pharmaceuticals is assessing QRX003 in a pediatric patient with Netherton Syndrome (NS), addressing the need for early treatment in this rare genetic disease.
Quoin Pharmaceuticals Advances QRX003 for Rare Skin Disorders, Expands Clinical Trials
Quoin Pharmaceuticals initiates an investigator-led clinical study in New Zealand to evaluate QRX003 for Peeling Skin Syndrome, a condition with no approved treatments.
Quoin Pharmaceuticals Advances QRX003 Clinical Programs for Rare Skin Diseases
Quoin Pharmaceuticals initiates a clinical study in New Zealand for QRX003 targeting Peeling Skin Syndrome, a condition with no approved treatments.
Quoin Pharmaceuticals Initiates Clinical Testing of QRX003 in Pediatric Netherton Syndrome Patient
Quoin Pharmaceuticals has begun clinical testing of QRX003 in a young child with Netherton Syndrome at Children’s Health Ireland in Dublin.
Quoin Pharmaceuticals Initiates Clinical Testing of QRX003 in Pediatric Netherton Syndrome Patient
Quoin Pharmaceuticals has begun clinical testing of QRX003 in a young child with Netherton Syndrome at Children's Health Ireland, marking the first evaluation in a pediatric patient.
Quoin Pharmaceuticals Initiates Clinical Testing of QRX003 in Pediatric Netherton Syndrome
Quoin Pharmaceuticals has begun clinical testing of QRX003 in a young child with Netherton Syndrome, a rare genetic disease with no approved treatments.
Quoin Pharmaceuticals Initiates Clinical Testing of QRX003 in Pediatric Netherton Syndrome Patient
Quoin Pharmaceuticals has begun clinical testing of QRX003 in a young child with Netherton Syndrome at Children’s Health Ireland, marking the first evaluation of the drug in a pediatric patient.
Quoin Pharmaceuticals Initiates Pediatric Trial of QRX003 for Netherton Syndrome
Quoin Pharmaceuticals has begun clinical testing of QRX003 in a pediatric patient with Netherton Syndrome in Dublin.
Quoin Pharmaceuticals Expands Netherton Syndrome Clinical Trials to the UK
Quoin Pharmaceuticals expands its Netherton Syndrome (NS) clinical trials to include two new sites in the United Kingdom.